Drug shortage
Pramlintide Acetate Injection · AstraZeneca AB
FDA drug shortage · To Be Discontinued · updated Oct 27, 2025
Key facts
| Generic name | Pramlintide Acetate Injection |
|---|---|
| Company | AstraZeneca AB |
| Presentation | SymlinPen® 60 , Injection, 1000 ug/1 mL (NDC 0310-6615-02) |
| Dosage form | Injection |
| Status | To Be Discontinued |
| Therapeutic category | Endocrinology/Metabolism |
| Package NDCs | 0310-6615-02 |
| First posted | Oct 27, 2025 |
| Last updated | Oct 27, 2025 |
| Discontinued | Oct 27, 2025 |
At a glance
- 1–9 Package NDCs affected
- 1–9 FDA shortage records for this drug
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug shortages
The FDA Drug Shortages Database lists current and resolved shortages of drugs, with presentations, affected NDCs and reasons reported by manufacturers.
Source: U.S. Food and Drug Administration (FDA), Drug Shortages Database · Source date: